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Background: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta
(Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late
onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies.
Discussion: These therapies are based on the assumption that Aβ accumulation is the primary pathogenic trigger of AD.
Current evidence suggests that Aβ may actually accumulate as part of an adaptive response to long-term chronic brain
stress stimuli that would make more suitable candidates for therapeutic intervention.
Summary: At this juncture it is no longer unreasonable to suggest that further iterations of anti-Aβ therapies should be
halted. Clinicians and researchers should instead direct their attention toward greater understanding of the biological
function of Aβ both in healthy and demented brains, as well as the involvement of long-term chronic exposure to stress
in the etiology of AD.
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According to reports published in the New England
Journal of Medicine, the phase 3 clinical trials of two
high-profile Alzheimer’s disease (AD) antibodies against the
aggregation-prone peptide amyloid beta (Aβ), bapineuzu-
mab and solanezumab, have failed to improve clinical out-
comes in patients with late onset AD [1-3]. Along with
their predecessors, these treatments have been informed by
the long-standing amyloid hypothesis, and are the latest ex-
amples in a long list of unsuccessful attempts to treat AD
with anti-amyloid therapies. Along with a chorus of others,
we have previously argued against the assumption that Aβ
accumulation is the primary early pathogenic trigger of AD
[4-8]. An unintended consequence of that assumption,
which contributes to the continued failure of anti-amyloid
clinical trials, is that affirmative diagnosis of AD-type de-
mentia can only occur when the presence of Aβ accumula-
tion in the brain is confirmed. However, recent imaging
studies confirm previous observations of Aβ accumulation
in a significant proportion of non-demented individuals
[4,9,10]. Conversely, a sizable proportion of patients* Correspondence: ssoriano@llu.edu
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accumulation-even though neurodegeneration is in pro-
gress [4,11]. Remarkably, rather than concluding that Aβ
status is not a reliable marker for the early stages of clinical
AD, a consensus has been reached in which clinically diag-
nosed AD patients without Aβ are classified as not suffer-
ing from AD. This line of thought is not scientifically
warranted, as there is no evidence to assume that clinical
AD cases with and without Aβ accumulation are etiologic-
ally different. Nevertheless, it has been used, in the EXPED-
ITION 3 phase of the ongoing solanezumab trial, to justify
the exclusion of approximately 25% of patients in the
study-all of whom were clinically diagnosed with mild AD,
but whose imaging data showed no Aβ accumulation [1,3].
Discussion
We submit that such course of action is logically flawed
on two different fronts. Firstly, current imaging methods
cannot detect the soluble Aβ oligomers that solanezumab
is thought to remove but that are, according to the amyl-
oid hypothesis itself, the bona fide pathogenic trigger of
the disease [12-14]. Thus, by eliminating all patients diag-
nosed with clinical AD but lacking Aβ plaques, all the
subjects that would potentially benefit from the trial arel Ltd.; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
.
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ale for following patients in whom Aβ plaques are already
detectable, since the presence of those plaques occurs, ac-
cording to the amyloid hypothesis itself, too late in the
disease for treatment to be effective and does not neces-
sarily correlate with neurodegeneration [3,12-18]. In ef-
fect, the current course of action helps to perpetuate a
tautological argument: the a priori assumption that Aβ is
the cause of AD is used to reject any clinical case in which
no Aβ increase is apparent.
Figure 1 further illustrates what we believe is the
flawed rationale on which anti-amyloid clinical trials are
based. Cognitive status assessment and Aβ imaging data
lead, according to the amyloid hypothesis, to a division
of the population into four distinct groups (Figure 1A),
which are: patients who are cognitively healthy (normal
cognition, NC; Figure 1A, 4), patients who are cognitively
healthy but accumulate Aβ (normal cognition with Aβ,
NC-Aβ; Figure 1A, 2), patients with neurodegeneration
who have clinical AD symptoms but no Aβ accumulation
(neurodegeneration-first AD, NDF-AD; Figure 1A, 3), and
finally, patients who have neurodegeneration, clinical AD
symptoms, and Aβ accumulation (Aβ-first AD, AF-AD;
Figure 1A, 5) [3,4,11]. According to the amyloid hypoth-
esis, of all the observed populations, only the latter can be
considered, by definition, as suffering from dementia of
the AD type, and only group 4 should be considered as
appropriate normal cognition controls in clinical trials.
The ongoing insistence on failing anti-amyloid therap-
ies is anchored on the belief that late onset AD primarilyFigure 1 Comparison of the amyloid and adaptive response hypothe
separate the total population into four distinct groups (1). These groups ar
Neurodegeneration-First AD (NDF-AD; 3), and Amyloid-First AD (AF-AD; 5).
to be studied moving forward in EXPEDITION 3 as disease state and contro
cannot be explained and do not fit the paradigm. B. Adaptive Response Hyp
variables (2) which may include, but are not limited to, oxidative stress, me
etc.), genetic factors, and inflammation response. These variables elicit an a
intensity of such response, the population falls into two groups, either Nor
and negative subpopulations.develops from aberrant Aβ biology that results in its ac-
cumulation. When the amyloid hypothesis was formed,
strong evidence clearly supported that assumption: Not
only do all familial cases of AD involve APP mutations that
cause dysregulated Aβ production, cases of trisomy 21
(Down syndrome; DS) in which APP was overexpressed
also exhibit Aβ plaque formation identical to that of AD
patients [19-21]. Since both FAD and DS exhibit pathology
clearly linked to Aβ production, late onset AD-which also
has abnormal Aβ-must also begin with Aβ. Such a conclu-
sion has subsequently been supported by innumerable ani-
mal and cell culture studies in which pathology is induced
by Aβ and rescued by its removal [22-25]. Given these find-
ings, the thinking currently guiding AD clinical trials con-
cludes that Aβ-modifying therapies simply must be capable
of preventing late-onset AD if administered correctly.
However, this line of reasoning does not account for
numerous other current observations. For example,
while all cases of FAD can be linked to a relatively small
number of mutations directly affecting APP processing,
this is never the case with late-onset AD [26,27]. In fact,
in the largest genetic analyses of late-onset AD to date,
the polymorphisms commonly observed are nearly all
associated with cholesterol metabolism, endocytosis (an
essential part of cholesterol processing), and inflamma-
tion [28-30] This evidence, together with imaging stud-
ies showing that Aβ accumulation can be uncoupled
from disease initiation, strongly argue against Aβ as an
early pathogenic trigger of late onset AD and, therefore,
as a suitable therapeutic target [9-11].ses. A. Amyloid Hypothesis Cognitive tests and amyloid imaging
e: Normal Cognition (NC; 4), NC with Aβ accumulation (NC-Aβ; 2),
Under this hypothesis, only the AF-AD and NC groups (4,5) are going
l, whereas the NC-Aβ and NDF-AD groups (2,3) are ignored, as they
othesis The total population (1) is differentiated by a set of stress
tabolism dysregulation (cholesterol homeostasis, insulin resistance,
daptive response in the brain and, depending on the nature and
mal Cognition (NC) (3) or AD (4), both of which contain Aβ positive
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evidence begins with abandoning the assumption that
FAD and late onset AD are etiologically comparable.
Doing so will help create the right context for the study
of the role of Aβ in health and disease, a role we do not
currently understand. In that regard, note that virtually
every experimental in vitro and in vivo model demon-
strating Aβ harm and subsequent improvement upon its
removal is, at best, a model of FAD. By definition, these
models begin with the overexpression of Aβ itself, a
pathogenic course that does not occur in late onset AD
[22-25]. In contrast, if FAD were considered not as an
accelerated version of late onset AD, but rather as a sub-
set of AD presentations that is etiologically different, we
could begin to explore the bona fide pathogenic triggers
of late onset AD and design evidence-based therapies.
In that regard, several hypotheses that are not
amyloid-centric have been proposed, although few have
gained significant traction [6,31-35]. Unlike in the past,
however, numerous independent researchers have now
gathered sufficient information to strongly support a
reworked conceptualization of late onset AD. Our re-
cently proposed Adaptive Response Hypothesis synthe-
sizes this work, proposing that Aβ may accumulate as
part of an adaptive response to chronic brain stress stim-
uli [6]. These stress stimuli constitute the bona fide
pathogenic triggers of late onset AD and, therefore,
would be suitable candidates for therapeutic intervention
[5-7,32,36]. In this model, illustrated in Figure 1B, the
total population (Figure 1B, 1) can be affected by
chronic stress stimuli (Figure 1B, 2) which may include,
but are not limited to, oxidative stress, metabolic dysreg-
ulation (cholesterol homeostasis, insulin resistance, etc.),
genetic factors, and inflammatory response [7,36]. Each
of these stimuli is capable of eliciting a response in
which Aβ is produced, and the nature of that response
(not the total amount of Aβ that may accumulate in par-
allel) determines progression into clinical AD [5,6]. Ul-
timately this leads to the observed division, shown in
Figure 1B, into individuals with normal cognition (NC;
Figure 1B, 3) and those clinically diagnosed with AD
(AD; Figure 1B, 4), both of which may be further divided
into Aβ positive and Aβ negative subpopulations [6,32].
According to this view, therapeutic approaches must
address the biology of the chronic stressors that initiate
the disease, not the Aβ accumulation that (unlike in
FAD) may, or may not, occur during the course of the
disease. This offers numerous potential avenues to ex-
plore in the battle against AD. In fact, research into
aging, cholesterol regulation, and metabolic disorders
such as diabetes all can potentially be applied to AD.
Conceiving of the disease in this open-ended, systemic
fashion will allow clinicians and scientists to identify
new patterns and possibilities for therapy. For example,early research has shown that metabolism in the AD
brain is aberrant in ways that are not currently looked
for in the periphery [37,38]. Following this pathway,
early treatment intranasal insulin has actually shown
some promise in treating cognitive decline [38]. Simi-
larly, might drugs enhancing neural plasticity empower
the brain’s stress response in old age? [39].
Finally, it is worth noting that anti-amyloid therapies
may not simply result in neutral outcomes. Our hypoth-
esis predicts that Aβ removal will interfere with brain
homeostasis, and mounting evidence suggests that well-
regulated Aβ is important for healthy brain functions
such as memory formation-a function that is critical to
clinical outcome measurements [40-43]. At the same
time, even the most recent bapineuzumab trial continues
to be limited by edema formation, a symptom highly as-
sociated with cerebral amyloid angiopathy, the damaging
vascular amyloid deposition that often co-occurs with
AD [2,3,44]. Thus, the possibility must be considered
that current therapies designed around the bulk removal
of Aβ may not simply fail, but be actively harmful by
hindering the very functionality they hope to preserve.
In summary, millions of research dollars, both private
and public, are annually expended on anti-Aβ therapies
that do not work and are based on a logically flawed hy-
pothesis. At this point in time it is no longer unreason-
able to suggest that further iterations of anti-Aβ
therapies may not be in the best interest of late onset
AD patients. Clinicians and researchers should instead
direct their attention toward better understanding of the
biological function of Aβ in the healthy brain, and the
ways in which chronic stress over decades can negatively
affect the brain.Summary
 The authors contend that the amyloid cascade
hypothesis is no longer supported by the majority of
experimental evidence
 Proposed elimination of patients from
EXPEDITION 3 of the solanezumab Phase III trial
based on Aβ imaging is fundamentally flawed
 Aβ-centric therapeutic studies promote a
tautological definition of Alzheimer’s disease in
which the a priori assumption that Aβ is the
primary causative factor is used to exclude patients
exhibiting contrary symptoms
 An adaptive response hypothesis summarizes a
diverse body of experimental evidence and is able to
account for all AD-related presentations
 Such a hypothesis provides new opportunities for
research and potential therapies that the amyloid
cascade hypothesis does not
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